Zobrazeno 1 - 10
of 31
pro vyhledávání: '"M. S. Runge"'
Publikováno v:
European Heart Journal. 17:55-60
The ability of thrombolytic therapy to lower mortality in patients with acute myocardial infarction was first demonstrated in 1986 by the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico. In the ensuing 10 years, large effor
Publikováno v:
Methods in molecular medicine. 51
In situ hybridization (ISH) is employed principally to detect mRNA within cells and tissues. ISH begins with the synthesis of a nucleic acid probe complementary in sequence to a cellular target. Through incorporation of a radioactive nucleotide into
Autor:
N R, Madamanchi, M S, Runge
Publikováno v:
Methods in molecular medicine. 51
Western blotting is employed for the detection of proteins and other macromolecules immobilized on nitrocellulose membranes. This rapid and sensitive method enables the identification and quantification of a specific protein from cell lysates or a mi
Publikováno v:
Molecular and cellular biochemistry. 212(1-2)
The vasopressor octapeptide, angiotensin II (Ang II), exerts homeostatic responses in cardiovascular tissues, including the heart, blood vessel wall, adrenal cortex and liver (a major source of circulating plasma proteins). One of the effects of Ang
Autor:
D L, Ware, M S, Runge
Publikováno v:
The American journal of the medical sciences. 318(5)
Autor:
C, Patterson, J, Ruef, N R, Madamanchi, P, Barry-Lane, Z, Hu, C, Horaist, C A, Ballinger, A R, Brasier, C, Bode, M S, Runge
Publikováno v:
The Journal of biological chemistry. 274(28)
Thrombin is a potent vascular smooth muscle cell (VSMC) mitogen. Because recent evidence implicates reactive oxygen intermediates (ROI) in VSMC proliferation in general and atherogenesis in particular, we investigated whether ROI generation is necess
Autor:
C R, deFilippi, M S, Runge
Publikováno v:
Cardiology clinics. 17(2)
With an understanding of the pathophysiology of ACS and an increasing number of early therapeutic options, there has been a shift in focus from ruling-out MI to identifying and stratifying risk in all patients with potential ACS. The presenting sympt
Publikováno v:
The Journal of biological chemistry. 272(13)
The endothelial cell type-specific tyrosine kinase KDR/flk-1 is a receptor for vascular endothelial growth factor and a critical regulator of endothelial cell growth and development. To study mechanisms of endothelial cell differentiation and gene re
Publikováno v:
Annals of hematology. 73
Large efforts have been undertaken to develop more effective and safer thrombolytic agents than those currently used in clinical practice. In addition, the value of adjunctive agents influencing thrombotic and thrombolytic processes could be shown an
Publikováno v:
Annals of hematology. 73
Thrombolysis today has become a routine option not only in the treatment of acute myocardial infarction but also in many other manifestations of thromboembolic disease. Until one decade ago, only two plasminogen activators, streptokinase and urokinas